VC investing: Opportunities in a high interest rate environment
Richard Moore, Co-Head of Investments, gives his analysis on how a higher bank rate may affect the investment decisions made, and his outlook for the portfolio.
Richard Moore, Co-Head of Investments, gives his analysis on how a higher bank rate may affect the investment decisions made, and his outlook for the portfolio.
Oxford BioTherapeutics’s partner has dosed first patient in phase 2 trial that has potential to revolutionise treatment.
Wonderhood have been commissioned to produce a second season of Super Surgeons: A Chance at Life.
Laverock Therapeutics to demonstrate breadth of therapeutic applications of gene silencing platform at European Society of Gene & Cell Therapy.
Artificial Intelligence (AI), has emerged as a disruptive force with the potential to revolutionise industries across the globe. For investors and shareholders, AI represents a compelling opportunity.
Calculus has led an investment round into Laverock Therapeutics, a company developing a unique gene silencing platform for the creation of programmable advanced therapies.
Scancell achieve significant milestone for their cancer vaccine.
Calculus Q2 2023 Quarterly Update showcasing some great news stories from our portfolio companies.
Its new documentary explores the legacy of famed music art studio Hipgnosis.
The new trial is designed to build on preliminary data supporting the notion that OBT-076 is able to deliver immune priming in chemo-refractory, advanced cancer patients.